RecruitingNCT06649162
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Sponsor
Boryung Pharmaceutical Co., Ltd
Enrollment
10,000 participants
Start Date
Sep 30, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Eligibility
Min Age: 19 Years
Inclusion Criteria2
- Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
- Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.
Exclusion Criteria2
- Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1).
- Those who are expected to need insulin prescription during the study period.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06649162
Related Trials
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT0729648446 locations
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
NCT071694221 location
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
NCT068364791 location
High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes
NCT066884611 location
IH, Brain Health, and T2D
NCT071735431 location